Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kezar Life Sciences Inc (KZR)
NASDAQ:KZR
Holding KZR?
Track your performance easily
KZR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.20 - $11.35
Previous Close$6.38
Volume75.11K
Average Volume (3M)106.94K
Market Cap
$47.57M
Enterprise Value-$84.93M
Total Cash (Recent Filing)$148.39M
Total Debt (Recent Filing)$16.91M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Mar 13, 2025EPS Estimate
-$2.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.15
Shares Outstanding7,296,222
10 Day Avg. Volume335,102
30 Day Avg. Volume106,936
Standard Deviation0.24
R-Squared0.00268
Alpha0.00553
Financial Highlights & Ratios
Price to Book (P/B)0.35
Price to Sales (P/S)6.65
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.13
Enterprise Value/Ebitda0.93
Forecast
1Y Price Target
$9.00Price Target Upside41.07% Upside
Rating ConsensusHold
Number of Analyst Covering4
Kezar Life Sciences News
Bulls Say, Bears Say
Bulls Say
Business DevelopmentPotential exists for favorable monetization of zetomipzomib through business development opportunities.
Clinical Trial SafetyNo Grade 4 or Grade 5 severe adverse events have been observed in the PORTOLA trial.
Financial StabilityKezar ended with approximately $148 million in cash, cash equivalents, and marketable securities, which is expected to last well into 2025.
Bears Say
Buyout OfferThe board unanimously concluded that the Concentra proposal substantially undervalues Kezar.
Clinical TrialsA partial clinical hold has been placed on Phase 2a of zetomipzomib in autoimmune hepatitis by the FDA, adding uncertainty to the program.
Safety ConcernsIn October Kezar discontinued the PALIZADE Ph 2b trial of zetomipzomib in lupus nephritis following the report of n=4 fatal adverse events.
---
Ownership Overview
13.77% Insiders
13.73% Mutual Funds
18.59% Other Institutional Investors
50.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KZR FAQ
What was Kezar Life Sciences Inc’s price range in the past 12 months?
Kezar Life Sciences Inc lowest stock price was $5.20 and its highest was $11.35 in the past 12 months.
What is Kezar Life Sciences Inc’s market cap?
Currently, no data Available
When is Kezar Life Sciences Inc’s upcoming earnings report date?
Kezar Life Sciences Inc’s upcoming earnings report date is Mar 13, 2025 which is in 81 days.
How were Kezar Life Sciences Inc’s earnings last quarter?
Kezar Life Sciences Inc released its earnings results on Nov 12, 2024. The company reported -$2.78 earnings per share for the quarter, beating the consensus estimate of -$3.148 by $0.368.
Is Kezar Life Sciences Inc overvalued?
According to Wall Street analysts Kezar Life Sciences Inc’s price is currently Undervalued.
Does Kezar Life Sciences Inc pay dividends?
Kezar Life Sciences Inc does not currently pay dividends.
What is Kezar Life Sciences Inc’s EPS estimate?
Kezar Life Sciences Inc’s EPS estimate is -$2.88.
How many shares outstanding does Kezar Life Sciences Inc have?
Kezar Life Sciences Inc has 7,296,222 shares outstanding.
What happened to Kezar Life Sciences Inc’s price movement after its last earnings report?
Kezar Life Sciences Inc reported an EPS of -$2.78 in its last earnings report, beating expectations of -$3.148. Following the earnings report the stock price went up 0.668%.
Which hedge fund is a major shareholder of Kezar Life Sciences Inc?
Among the largest hedge funds holding Kezar Life Sciences Inc’s share is Wexford Capital LP. It holds Kezar Life Sciences Inc’s shares valued at N/A.
---
Kezar Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.00 (41.07% Upside)
$9.00 (41.07% Upside)
Blogger Sentiment
Bullish
KZR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 11.4%
Last 30 Days ▼ 11.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.94%
12-Months-Change
Fundamentals
Return on Equity
-54.72%
Trailing 12-Months
Asset Growth
-34.19%
Trailing 12-Months
Company Description
Kezar Life Sciences Inc
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
---
KZR Stock 12 Month Forecast
Average Price Target
$9.00
▲(41.07% Upside)
Technical Analysis
Best Analysts Covering KZR
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-17.53%
reiterated a buy rating last month
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -17.53% per trade.
---